DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of new information on the Company’s automated approach for the manufacture of personalized RNA-loaded dendritic cell-based immunotherapies. The Company’s advanced manufacturing process is complementary to its Arcelis™ technology, a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer. The presentation will be made today in a poster session at the International Society for Cellular Therapy 14th Annual Meeting in Miami, FL, by Tamara Monesmith, Argos’ Director of Process Development and Manufacturing.
